[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100640000":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":13,"locations":7,"responsibleParty":19,"collaborators":23,"id":27,"slug":28,"hasResults":29,"nctId":30,"briefTitle":31,"officialTitle":32,"acronym":7,"eligibilityCriteria":33,"healthyVolunteers":29,"sex":34,"minAge":35,"maxAge":7,"enrollmentInfo":36,"targetDuration":7,"studyType":39,"phases":7,"briefSummary":40,"conditions":41,"keywords":43,"overallStatus":50,"whyStopped":7,"lastUpdateSubmitDate":51,"lastUpdatePostDateStruct":52,"startDateStruct":55,"completionDateStruct":56,"leadSponsor":58,"locationsCount":7},{"fullName":5,"class":6},"Northwestern University","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"BEHAVIORAL","Set of implementation strategies","This is an observational implementation study. The research team does not assign or deliver any clinical interventions. T1D screening orders and blood draws occur as part of routine care at clinician discretion, and the study observes EHR outcomes and collects surveys\u002Finterviews.\n\nThe research team will deliver a set of implementation strategies (clinician education, clinician ordering reminders, and facilitation) to all participating clinics to enable routine screening adoption. These are clinic-wide activities and are not research 'interventions' assigned to participants, and clinical decisions remain at clinician discretion. These strategies will not be randomly assigned.",[14],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Rinad S Beidas, PhD","CONTACT","312-503-0546","Rinad.beidas@northwestern.edu",{"type":20,"investigatorFullName":21,"investigatorTitle":22,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","Rinad Beidas","Ralph Seal Paffenbarger Professor and Chair, Department of Medical Social Sciences",[24],{"name":25,"class":26},"Sanofi","INDUSTRY","100640000","universal-type-1-diabetes-screening-in-pediatrics-100640000",false,"NCT07612475","Universal Type 1 Diabetes Screening in Pediatrics","Feasibility of Implementing Type One Diabetes Screening in Pediatric Clinics","Inclusion Criteria:\n\nChildren\n\n\\- Clinics will be encouraged to select screening ages or visits that align with international consensus statements for screening during early childhood, mid-childhood, and preadolescence and routine U.S. well-child visit schedules, and that minimize workflow disruption and maximize screening completion, such as visits that already include blood draws for other routine tests (e.g., lead screening at age 2). Children who have visits at their clinic's selected ages will be eligible to have their data extracted from the electronic health record (EHR)\n\nParents\u002FCaregivers - All parents or legal guardians (hereafter, parents) who attended the well-child visit, who are eligible to have their child's EHR data extracted, and who are over age 18, will be eligible to complete the post-visit survey and interview.\n\nClinicians and Other Care Team Members\n\n* All pediatric primary care clinicians (i.e., physician \\[MD, DO\\], nurse practitioner, physician assistant) at participating clinics will be eligible to complete an interview.\n* All other care team members, including nurses, medical assistants, phlebotomists, and front desk staff at participating clinics will be eligible to complete an interview.\n\nExclusion Criteria:\n\n\\- Parents who have opted-out of survey recruitment at their clinic will not be eligible for the survey\u002Finterview.","ALL","1 Year",{"count":37,"type":38},9500,"ESTIMATED","OBSERVATIONAL","This study examines how population-based screening for type 1 diabetes (T1D) using islet autoantibodies (i.e., immune system proteins) can be incorporated into pediatric primary care during routine well-child visits. The project evaluates whether this screening approach, supported by the study's implementation approach, is feasible, acceptable, and appropriate for clinicians, parents, and other key constituent groups. The study also explores how often clinicians order the test, how often patients complete it, and how often clinicians document stages of early-stage T1D in the patients' electronic health records. Insights from parents, clinicians, other care team members, pediatric endocrinologists, and national and regional experts will inform future scale-up efforts and practical strategies to improve early detection of T1D in pediatric practices across the United States.",[42],"Type 1 Diabetes (T1D)",[44,45,46,47,48,49],"Implementation Science","Pediatrics","Type 1 Diabetes","Universal Screening","Islet Autoantibodies","Population-based Screening","NOT_YET_RECRUITING","2026-07-16",{"date":53,"type":54},"2026-07-20","ACTUAL",{"date":53,"type":38},{"date":57,"type":38},"2027-10-19",{"name":5,"class":6}]